Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma: a treatable disease.

Joseph H Korn1

  • 1Arthritis Center, Boston University School of Medicine, MA 02118, USA.

Cleveland Clinic Journal of Medicine
|December 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.

Annals of the rheumatic diseases·2010
Same author

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

Arthritis and rheumatism·2009
Same author

Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.

Arthritis and rheumatism·2008
Same author

Outcome measurements in scleroderma: results from a delphi exercise.

The Journal of rheumatology·2007
Same author

Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

Arthritis and rheumatism·2006
Same author

Durometry for the assessment of skin disease in systemic sclerosis.

Arthritis and rheumatism·2006

New scleroderma treatments like bosentan and epoprostenol target vasoconstriction. Cyclophosphamide shows promise for treating scleroderma-associated interstitial lung disease, offering new hope for patients.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Pharmacology

Background:

  • Scleroderma is a complex autoimmune disease characterized by fibrosis and vasculopathy.
  • Vasoconstriction and interstitial lung disease (ILD) are significant complications impacting patient prognosis.

Purpose of the Study:

  • To review recent advancements in pharmacologic treatments for scleroderma.
  • To highlight therapies targeting the underlying mechanisms of scleroderma complications.

Main Methods:

  • Literature review of recent clinical trials and studies on scleroderma treatments.
  • Analysis of pharmacological agents targeting vasoconstriction and fibrotic processes.

Main Results:

  • Bosentan, an endothelin receptor antagonist, and epoprostenol, a prostacyclin, are effective in managing scleroderma-related vasoconstriction.

Related Experiment Videos

  • Emerging evidence suggests cyclophosphamide may be a beneficial treatment for scleroderma-associated interstitial lung disease.

    • Conclusions:

    • Targeted therapies have improved the management of scleroderma vasculopathy.
    • Cyclophosphamide represents a potential new therapeutic option for scleroderma-induced ILD, warranting further investigation.